Xolair in asthma therapy: An overview

Inflammation and Allergy - Drug Targets

Volumn 10, Issue 1, 2011, Pages 2-12

  Di Domenico, Monica ^a   Bisogno, Angelica ^a   Polverino, Mario ^b   de Rosa, Concetta ^b   Ricci, Vilma ^c   Capasso, Anna ^a  

^a UNIVERSITY OF SALERNO   (Italy)

^b Cava de' Tirreni Hospital   (Italy)

^c S Maria Incoronata Olmo Hospital   (Italy)

Author keywords

Allergy; Asthma; Ig E; Inflammation; Xolair

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIHISTAMINIC AGENT; BASILIXIMAB; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIT 322; BTI 322; CGP 51901; CGP 56901; CORTICOSTEROID; DACLIZUMAB; E 25; E 26; EFALIZUMAB; FLUTICASONE PROPIONATE; GAVILIMOMAB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 2 RECEPTOR ANTIBODY; MEDI 500; OKT 3; OKT 4; OMALIZUMAB; PLACEBO; SIPLIZUMAB; STEROID; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADD ON THERAPY; ALLERGIC ASTHMA; ALLERGIC REACTION; ALLERGIC RHINITIS; ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; AREA UNDER THE CURVE; ARTHRALGIA; ASTHMA; B LYMPHOCYTE ACTIVATION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFORMATIONAL TRANSITION; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DERMATITIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BINDING SITE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FRACTURE; HAY FEVER; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE SWELLING; LEG PAIN; LIMB PAIN; MEDIATOR RELEASE; NEOPLASM; OTALGIA; PAIN; PHARYNGITIS; PRURITUS; RESPIRATORY DISTRESS SYNDROME; REVIEW; SENSITIZATION; SINUSITIS; SKIN BRUISING; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

EID: 79551647538     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152811794352042     Document Type: Review

References (36)

1. Roth, S.; Zope, D. Phenothiazine derivatives for treatment of asthma. US20100130457, 2010.
2. Meurs, H.; Zaagsma, J.; Maarsingh, H.; Van Duin, M. Use of arginase inhibitors in the treatment of asthma and allergic rhinitis. US2010056480, 2010.
3. Brown, M.; Johnson, M.G.; Li, A.-R.; Liu, J.; Lively, S.E.; Medina, J.C.; Shen, W.; Wang, X.; Wang, Y. Compounds as CRTH2 and/or PGD2 receptors modulators and their use for treating asthma and allergic inflammation. EP2164828, 2010.
4. Brosz, M.; Kuhne, F. W.; Blaszkiewitz, K.; Isensee, T. Use of WF10 for treating allergic asthma, allergic asthma rhinitis and atopic dermatitis. EP2164502, 2010.
5. O'Toole, M.M.; Immermann, F. W.; Dorner, A. J.; Reddy, P. S.; Legault, H. M.;Whalen, K. A. Assessment of asthma and allergendependent gene expression. US20090155784, 2009.
6. Pearce, N.; Pekkanen, J.; Beasley, R. How much asthma is really attributable to atopy? Thorax, 1999, 54, 268-272.
7. Crystal-Peters, J.; Neslusan, C.; Crown, W.H.; Torres, A. Treating allergic rhinitis in patients with comorbid asthma department visits. J. Allergy Clin. Immunol., 2002, 109, 57-62.
8. Holgate, S.T.; Djukanovié, R.; Casale, T.; Bousquet, J. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: An update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy., 2005, 35, 408-416.
9. Malveaux, F.J.; Conroy, M.C.; Adkinson, N.F. Jr.; Lichtensterin, L.M. IgE receptors on human basophils. Relationship to serum IgE concentration. J. Clin. Invest., 1978, 62, 176-181.
10. Schneider, F. J.; Becker, C.; Bopp, T.; Jonuleit, H.; Schmitt, E. Specific activation of a regulatory T cell and its use for treatment of asthma, allergic disease, autoimmune disease, graft rejection and for tolerance induction. US2010074904, 2010.
11. Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet, 1967, 2, 951-953.
12. Chang, T.W. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol., 2000, 18, 157-162.
13. Fick, R. B.; Jardieu, P. M.; Schoenhoff, M. B.; Shire, S. J. Methods for treatment of allergic asthma. US20090087426, 2009.
14. Burrows, B.; Martinez, F.D.; Halonen, M.; Cline, M.G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med., 1989, 320, 271-277.
15. Borish, L.; Chipps, B.; Deniz, Y.; Gujrathi, S.; Zheng, B.; Dolan, C.M. Total serum IgE levels in a large cohort of patients with severe or difficult-to-treat asthma. Ann. Allergy Asthma Immunol., 2005, 95, 247-253.
16. Breedveld, F.C. Therapeutic monoclonal antibodies. Lancet, 2000, 355, 735-740.
17. Hook, W.A.; Zinsser, F.U.; Berenstein, E.H.; Siraganian, R.P. Monoclonal antibodies defining epitopes on human IgE. Mol. Immunol., 1991, 28, 631-639.
18. Presta, L.; Shields, R.; O'Connel, L.; Lahr, S.; Porter, J.; Gorman, C.; Jardieu, P. The binding site on human immunoglobulin E for its high affinity receptor. J. Biol. Chem., 1994, 269, 26368-26373.
19. Malveaux, F.J.; Conroy, M.C.; Adkinson, N.F.; Lichtenstein, L.M. IgE receptors on human basophils. Relationship to serum IgE concentration. J. Clin. Invest., 1978, 62, 176-181.
20. MacGlashan, D.W.; Bochner, B.S.; Adelman, D.C.; Jardieu, P.M.; Togias, A.; McKenzie-White, J.; Sterbinsky, S.A.; Hamilton, R.G.; Lichtenstein, L.M. Down-regulation of FcepsilonRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol., 1997, 158, 1438-1445.
21. Owen, C.E; Fox, H.G, Walker, C. Synergistic Combination of Xolair/Omalizumab/E25 With Immunosuppressive Agent. United States Patent Application 20080206237, 2008.
22. Lloyd, P.; Lowe, P.; Pascoe, S. Use of antibody-ligand binding to characterise diseases. United States Patent Application 20090136965, 2009.
23. Risk, C.G. Novel Uses For Anti-Ige Therapy. United States Patent Application 20090220496, 2009.
24. Skjønsberg, O.H.; Clench-Aas, J.; Leegaard, J.; Skarpaas, I.J.; Giaever, P.; Bartonova, A.; Modseng, J. Prevalence of bronchial asthma in schoolchildren in Oslo, Norway-comparison of data obtained in 1993 and 1981. Allergy 1995, 50, 806-810.
25. Tirimanna, P.R.S.; van Schayck, C.P.; den Otter, J.J.; van Weel, C.; van Herwaarden, C.L.; van den Boom, G.; van Grunsven, P.M.; van den Bosch, W.J. Prevalence of asthma and COPD in general practice in 1992: Has it changed since 1977? Br. J. Gen Pract., 1996, 46, 277-281.
26. Novak, N.; Bieber, T. Allergic and nonallergic forms of atopic diseases. J. Allergy Clin. Immunol., 2003, 112, 252-262.
27. Godard, P.; Chanez, P.; Siraudin, L.; Nicoloyannis, N.; Duru, G. Costs of asthma are correlated with severity: A 1-yr prospective study. Eur. Respir. J., 2002, 19, 61-67.
28. Jardieu, P. M.; Presta, L. G. Method of treating allergic disorders. US20010033842, 2001.
29. Robinson, C. B.; Ball, H. A. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-IgE antibody for treatment of asthma or chronic obstructive pulmonary disease. US20090263381, 2009.
30. Presta, L.G.; Lahr, S.J.; Shields, R.L.; Porter, J.P.; Gorman, C.M.; Fendly, B.M.; Jardieu, P. Humanization of an antibody directed against IgE. J. Immunol., 1993, 151, 2623-2632.
31. Humbert, M.; Beasley, R.; Ayres, J.; Slavin, R.; Hébert, J.; Bousquet, J.; Beeh, K.M.; Ramos, S.; Canonica, G.W.; Hedgecock, S.; Fox, H.; Blogg, M.; Surrey, K. Benefits of omalizumab as addon therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy, 2005, 60, 309-316.
32. Ayres, J.G.; Higgins, B.; Chilvers, E.R.; Ayre, G.; Blogg, M.; Fox, H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy, 2004, 59, 701-708.
33. Vignola, A.M.; Humbert, M.; Bousquet, J.; Boulet, L.P.; Hedgecock, S.; Blogg, M.; Fox, H.; Surrey, K. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy, 2004, 59, 709-717.
34. Busse, W.W. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am. J. Respir. Crit. Care Med., 2001, 164, S12-17.
35. Solèr, M.; Matz, J.; Townley, R.; Buhl, R.; O'Brien, J.; Fox, H.; Thirlwell, J.; Gupta, N.; Della Cioppa, G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J., 2001, 18, 254-261.
36. Holgate, S.T.; Djukanovic, R.; Casale, T.; Bousquet, J. Antiimmunoglobulin E treatment with omalizumab in allergic diseases: An update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy, 2004, 35, 408-416.